Pages that link to "Q41394300"

The following pages link to Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission (Q41394300):

Displaying 42 items.

• Targeted immunotherapy for pediatric solid tumors (Q26747703) (← links)
• Immunotherapy of Childhood Sarcomas (Q26795369) (← links)
• Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma (Q28069952) (← links)
• A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies (Q34484061) (← links)
• GD2-targeted immunotherapy and radioimmunotherapy (Q34625339) (← links)
• Glucan supplementation enhances the immune response against an influenza challenge in mice (Q35065181) (← links)
• Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study (Q35798960) (← links)
• Advances in Risk Classification and Treatment Strategies for Neuroblastoma (Q36053801) (← links)
• Antitumor activity of orally administered maitake α-glucan by stimulating antitumor immune response in murine tumor (Q36302508) (← links)
• Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin (Q36782374) (← links)
• Tumor-associated macrophages: from basic research to clinical application (Q37671174) (← links)
• New immunotherapeutic strategies for the treatment of neuroblastoma (Q38389316) (← links)
• Racotumomab for treating lung cancer and pediatric refractory malignancies. (Q38745411) (← links)
• Tumor-Associated Macrophages as Target for Antitumor Therapy. (Q39403895) (← links)
• Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults (Q40700335) (← links)
• Tumor-associated macrophages, potential targets for cancer treatment. (Q41318642) (← links)
• MafB silencing in macrophages does not influence the initiation and growth of lung cancer induced by urethane (Q41582466) (← links)
• MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy. (Q47108370) (← links)
• Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors (Q47118215) (← links)
• Anti-GD2 immunotherapy for neuroblastoma. (Q47554435) (← links)
• The role of macrophage phenotype in regulating the response to radiation therapy (Q49634844) (← links)
• Neuroblastoma: clinical and biological approach to risk stratification and treatment (Q52639269) (← links)
• Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles. (Q52657150) (← links)
• High-Risk Neuroblastoma Treatment Review (Q57167141) (← links)
• β-glucans as potential immunoadjuvants: A review on the adjuvanticity, structure-activity relationship and receptor recognition properties (Q57167898) (← links)
• Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients (Q57455912) (← links)
• Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial (Q57492798) (← links)
• Maintenance DFMO Increases Survival in High Risk Neuroblastoma (Q59129117) (← links)
• Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy (Q88440609) (← links)
• Neuroblastoma (Q88730901) (← links)
• Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies (Q89517131) (← links)
• Monitoring Immune Responses in Neuroblastoma Patients during Therapy (Q89896175) (← links)
• Targets and Antibody Formats for Immunotherapy of Neuroblastoma (Q90299989) (← links)
• Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial (Q90394270) (← links)
• Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma (Q91644156) (← links)
• Yeast-Derived β-Glucan in Cancer: Novel Uses of a Traditional Therapeutic (Q92178008) (← links)
• Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma (Q92529625) (← links)
• A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogens (Q92538747) (← links)
• Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial (Q92898218) (← links)
• Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy (Q98178304) (← links)
• Unique repertoire of anti-carbohydrate antibodies in individual human serum (Q99608500) (← links)
• The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans (Q108768848) (← links)